Understanding Your Product’s Immunogenicity and Immunological Impact
The immune system has wide ranging and complex interactions that can affect the function and efficacy of biopharmaceutical products Abzena has developed a range of assays and technologies to help you harness, evade and understand the immune response to biopharmaceutical products.
Therapeutic antibodies and proteins can induce an immune response in patients leading to the development of anti-drug antibodies (ADAs). These potentially lead to reduced efficacy through rapid clearance or neutralisation of the drug or toxicity due to cross-reaction with proteins in the body. We have developed accurate and sensitive ex vivo and rapid in silico technologies to assess the potential for therapeutic antibodies and proteins to produce an immunogenic response in patients.
We can undertake a wide range of bespoke and custom assays backed by expertise gained from over 10 years of immunology and immunogenicity research.
Therapeutic proteins and antibodies can potentially activate innate and adaptive immune responses resulting in rapid and excessive cytokine release, which can produce significant toxicity. We have developed and validated an enhanced in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine release syndrome prior to it being tested in clinical trials.